<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Famotidine - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Famotidine</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../index.html">Home</a>
        <a class="btn small" href="../medications.html">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">GI</div>
      <h1>Famotidine</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Famotidine 20mg Tablets</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Dyspepsia / heartburn / acid indigestion (intermittent)</strong>
            <ul>
              <li>20 mg PO once daily as needed OR 20 mg PO before a known trigger meal (per product directions/guidance)</li>
            </ul>
          </li>
          <li><strong>GERD symptoms (short-term)</strong>
            <ul>
              <li>20 mg PO twice daily (e.g., morning and bedtime) for a short course; reassess</li>
            </ul>
          </li>
          <li><strong>Suspected gastritis/ulcer symptoms (selected cases; provider-directed)</strong>
            <ul>
              <li>20 mg PO twice daily short-term; reassess and consider escalation if red flags or persistent symptoms</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Relief/prevention of heartburn, acid indigestion, sour/upset stomach due to excess acid</li>
          <li>Symptomatic GERD (short-term management)</li>
          <li>Selected acid-related conditions where H2-blocker is appropriate (provider-directed)</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Hypersensitivity to famotidine or other H2-receptor antagonists</li>
          <li>Renal impairment: dose reduction may be required (risk of CNS effects in significant impairment)</li>
          <li>Red flags requiring reassessment/escalation: GI bleeding, persistent vomiting, unexplained weight loss, progressive dysphagia, severe/persistent pain</li>
          <li>Consider drug interactions/absorption issues for drugs needing acidic gastric pH (rare onboard relevance; use judgment)</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Headache, dizziness</li>
          <li>Constipation or diarrhea</li>
          <li>Rare: confusion (higher risk in older adults or renal impairment)</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li>PO tablet; may take with or without food</li>
          <li>For nocturnal symptoms, bedtime dosing may help</li>
          <li>If using antacids as well, separate if needed for symptom control (local practice)</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Symptom response within 24â€“48 hours</li>
          <li>Ongoing need (avoid indefinite use without reassessment)</li>
          <li>Watch for CNS effects in older adults or those with renal impairment</li>
          <li>Screen for red flags and escalate evaluation when present</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Limited diagnostics: treat symptomatically but maintain a low threshold to reassess for GI bleed or cardiac mimics of epigastric pain</li>
          <li>Document trigger patterns (diet, NSAID use, alcohol, stress) and consider risk reduction onboard</li>
          <li>If frequent NSAID use (e.g., ibuprofen/naproxen), reassess GI risk and consider gastroprotection strategy per local guidance</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (famotidine tablets): <a href="https://pdf.hres.ca/dpd_pm/00025706.PDF" target="_blank">https://pdf.hres.ca/dpd_pm/00025706.PDF</a></li>
          <li>Health Canada nonprescription labelling standard (famotidine): <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/famotidine-labelling-standards-non-prescription-drugs.html" target="_blank">https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/famotidine-labelling-standards-non-prescription-drugs.html</a></li>
          <li>Health Canada product monograph (Auro-Famotidine 20 mg): <a href="https://pdf.hres.ca/dpd_pm/00078170.PDF" target="_blank">https://pdf.hres.ca/dpd_pm/00078170.PDF</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
